BDSX logo

Biodesix (BDSX) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

28 October 2020

Indexes:

Not included

Description:

Biodesix (BDSX) is a biotechnology company focused on developing diagnostic tests for lung cancer. They use advanced technology to analyze blood samples, helping doctors make better treatment decisions. Their goal is to improve patient outcomes through personalized medicine and innovative testing solutions.

Key Details

Price

$1.47

Annual Revenue

$49.09 M(+28.46% YoY)

Annual EPS

-$0.64(+58.71% YoY)

Annual ROE

-414.09%

Beta

0.58

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 01, 2024

Recent annual earnings:

Mar 01, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

16 Sept '24 Scotiabank
Sector Outperform
26 July '24 Craig-Hallum
Buy
13 May '24 TD Cowen
Buy
03 May '24 Lake Street
Buy
04 Mar '24 Canaccord Genuity
Buy
07 Dec '23 Canaccord Genuity
Buy
12 May '22 Morgan Stanley
Equal-Weight
20 Apr '22 Cowen & Co.
Outperform
17 Nov '21 Morgan Stanley
Equal-Weight
12 May '21 Morgan Stanley
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BDSX
zacks.com20 November 2024

The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
BDSX
zacks.com01 November 2024

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

Biodesix Announces Third Quarter 2024 Results and Highlights
Biodesix Announces Third Quarter 2024 Results and Highlights
Biodesix Announces Third Quarter 2024 Results and Highlights
BDSX
globenewswire.com01 November 2024

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo.

Biodesix to Participate in Three Investor Conferences in November
Biodesix to Participate in Three Investor Conferences in November
Biodesix to Participate in Three Investor Conferences in November
BDSX
globenewswire.com29 October 2024

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
BDSX
businesswire.com18 October 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webca.

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
BDSX
businesswire.com07 October 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, Massachusetts on Tuesday, October 8 at 10:20 am ET. The presentation will detail the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment in over 35,000 patients consecutively tested in a real-world clinical setting. Guidelines recommend that.

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
BDSX
zacks.com07 August 2024

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago.

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
BDSX
businesswire.com18 June 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures. After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nomina.

Biodesix to Participate in Two Investor Conferences in June
Biodesix to Participate in Two Investor Conferences in June
Biodesix to Participate in Two Investor Conferences in June
BDSX
businesswire.com28 May 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44th Annual Growth Stock Conference Presentation and 1x1 Meetings Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT Location: Chicago, IL Jefferies Global Healthcare Conference Presentation and 1x1 Meetings Presentation Date.

3 Penny Stocks to Turn $999 Into $1 Million: January 2024
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
BDSX
InvestorPlace26 January 2024

Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Biodesix?
  • What is the ticker symbol for Biodesix?
  • Does Biodesix pay dividends?
  • What sector is Biodesix in?
  • What industry is Biodesix in?
  • What country is Biodesix based in?
  • When did Biodesix go public?
  • Is Biodesix in the S&P 500?
  • Is Biodesix in the NASDAQ 100?
  • Is Biodesix in the Dow Jones?
  • When was Biodesix's last earnings report?
  • When does Biodesix report earnings?
  • Should I buy Biodesix stock now?

What is the primary business of Biodesix?

Biodesix (BDSX) is a biotechnology company focused on developing diagnostic tests for lung cancer. They use advanced technology to analyze blood samples, helping doctors make better treatment decisions. Their goal is to improve patient outcomes through personalized medicine and innovative testing solutions.

What is the ticker symbol for Biodesix?

The ticker symbol for Biodesix is NASDAQ:BDSX

Does Biodesix pay dividends?

No, Biodesix does not pay dividends

What sector is Biodesix in?

Biodesix is in the Healthcare sector

What industry is Biodesix in?

Biodesix is in the Diagnostics & Research industry

What country is Biodesix based in?

Biodesix is headquartered in United States

When did Biodesix go public?

Biodesix's initial public offering (IPO) was on 28 October 2020

Is Biodesix in the S&P 500?

No, Biodesix is not included in the S&P 500 index

Is Biodesix in the NASDAQ 100?

No, Biodesix is not included in the NASDAQ 100 index

Is Biodesix in the Dow Jones?

No, Biodesix is not included in the Dow Jones index

When was Biodesix's last earnings report?

Biodesix's most recent earnings report was on 1 November 2024

When does Biodesix report earnings?

The next expected earnings date for Biodesix is 28 February 2025

Should I buy Biodesix stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions